Taxonomy
The 2020 Winter CMTA Report
Be the Change: From attitude to exercise to research, in 2020 our CMTA family is committed to be the change we want to see in the world of CMT.David Coldiron Joins CMTA Board of Directors
The Charcot-Marie-Tooth Association (CMTA), the national patient advocacy organization leading CMT research, today announced the appointment of David Coldiron to its Board of Directors.A Message from Patients to Patients
As you’ll learn from watching this video by two young members of our CMT family, tiredness, exhaustion, fatigue and “sluggishness” are all part of having CMT.Another $500,000 Pledge to Type 2 Research!
Bruce Chizen, a special advisor to the Board of Directors, will match donations to CMT2 research on a one-to-one basis, up to $500,000.The 2019 Fall CMTA Report
The Type 2 Issue: We have set the stage for a number of Type 2 breakthroughs on our way to treatments for CMT.New Gene Therapy, Type 1/Type 4 Research Projects Approved
The CMTA today announced another $335,000 in grants to top CMT scientists leading the field in CMT Type 1 research. The grants cover work on types 1A, 1B and 1X and other demyelinating forms of CMT, including type 4. New Gene Therapy Development Program for CMT2A
Passage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).
$1 Million Gift Pledged to CMT Type 2 Research!
Bob and Gail Buuck are big believers in “impact giving,” They have pledged a $1 million gift to advance CMT Type 2 research.2019 Summer CMTA Report
All in the Family: The many branches of the CMTA family tree—the patients, the families that support them and the doctors who treat them.Remembering Camp Footprint
Swim in a cool lake. Make a new friend. Practice archery or ride a horse. Remember what summer camp was like; then see what it was like at Camp Footprint, the only camp in the U.S. solely for kids with CMT.
